Study Description
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533,
LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis
suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an
adequate clinical profile for further clinical development.
Interventions
CFZ533
LOU064 100mg
LOU064 25mg
LYS006
MAS825
Placebo to CFZ533
Placebo to LOU064
Placebo to LYS006
Placebo to MAS825
Placebo to VAY736
VAY736
Eligibility Criteria
Inclusion Criteria:
- Patients with moderate to severe HS based on the number of lesions, fistulae and
anatomical areas involved
- Minimal body weight of 50 kg
- Able to communicate well with the investigator and understand and comply with the
requirements of the study, and the ability and willingness to conduct study visits
as per the study schedule
Exclusion Criteria:
- Use of other investigational drugs at the time of screening or before
- Women physiologically capable of becoming pregnant, unless they are using highly
effective methods of contraception
- Pregnant or lactating women
Other protocol-defined inclusion/exclusion criteria may apply
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.